Today: 20 March 2026
Mastercard stock price pulls back after earnings pop as layoffs loom — what to watch next week
31 January 2026
1 min read

Mastercard stock price pulls back after earnings pop as layoffs loom — what to watch next week

New York, Jan 31, 2026, 10:33 (EST) — Market closed.

  • Mastercard shares ended at $538.79, slipping 0.9% following a sharp 4.3% rise on Thursday.
  • The company surpassed profit estimates and announced around 4% job cuts, alongside a roughly $200 million charge in Q1.
  • Monday’s focus for investors will be on travel-related spending patterns, cost pressures, and how companies are responding after recent earnings reports.

Mastercard shares (NYSE: MA) ended Friday at $538.79, slipping 0.91% following a 4.29% surge the previous day. The stock fluctuated between $535.23 and $543.76, with roughly 4.31 million shares changing hands. Investing.com

The timing is tricky for the payments giant. Mastercard’s earnings and cost updates hit first, followed by insights from competitors — now traders face a weekend gap ahead of Monday’s open.

Mastercard reported fourth-quarter adjusted earnings of $4.76 per share, with net revenue hitting $8.8 billion. That marks an 18% rise from the same period last year, or 15% when adjusting for currency fluctuations. The company’s “gross dollar volume,” reflecting transaction values processed through its network, increased 7%. Cross-border spending — transactions made outside the cardholder’s home country — jumped 14%. S25 Q4cdn

The company surpassed Wall Street expectations and announced plans to cut roughly 4% of its global workforce amid a shift in investment focus. CEO Michael Miebach noted a strategic review will “result in reductions in some areas and roles,” alongside increased emphasis elsewhere. Executives pegged the restructuring charge at around $200 million for this quarter, Reuters reported. Reuters

Chief financial officer Sachin Mehra told analysts the company “expect[s] to record a one-time restructuring charge in Q1 of approximately $200 million.” Reuters

The sector background grew more turbulent as earnings rolled in. Visa topped first-quarter forecasts Thursday night, yet its cross-border volume growth eased to 12%. Analysts at Evercore ISI flagged “some weakness in cross-border trends” and noted a raised expense outlook. Reuters

American Express on Friday projected annual profits mostly above estimates, but a slight earnings shortfall dragged its stock lower. CFO Christophe Le Caillec told Reuters, “We’re not projecting any discontinuity,” while Truist analysts pointed to expenses from a Platinum card revamp, noting no obvious boost in new accounts. Reuters

Mastercard’s focus heading into next week isn’t just on a single quarter but on the longer-term trajectory. Investors are zeroing in on travel-related spending and cross-border activity as indicators of consumer strength. They’re also watching closely to see if cost reductions can happen alongside investment in new products without hurting margins.

The setup isn’t straightforward. A dip in discretionary spending, weaker travel numbers, or increased political scrutiny on card fees could quickly sour sentiment—especially following the recent two-day earnings rollercoaster.

The next major catalyst for the broader “consumer health” sector is the U.S. January jobs report due Feb. 6. Traders often see this data as a key test for stocks sensitive to consumer spending. Bureau of Labor Statistics

Stock Market Today

  • Regeneus Ltd (RGS.AX) Jumps 33% on Heavy Volume, Signals Short-Term Upside
    March 19, 2026, 10:42 PM EDT. Regeneus Ltd (RGS.AX) surged 33.33% to A$0.012 on March 20, 2026, driven by unusually heavy volume of 4.28 million shares, nearly seven times the average. The stock broke above its 50-day and 200-day moving averages, indicating increased short-term trader interest in this clinical-stage biotech focused on osteoarthritis and wound healing. Despite negative earnings per share and liquidity constraints, the price action reflects momentum trading in a volatile sector. Traders should watch intraday support at A$0.010 and resistance near the year high of A$0.020. With a Meyka AI rating of 64.90 (Grade B), the stock is rated HOLD amid high volatility and thin order books typical of small-cap biotechs on the Australian Securities Exchange (ASX).
Micron stock faces Monday test after Friday slide as Apple flags rising memory costs
Previous Story

Micron stock faces Monday test after Friday slide as Apple flags rising memory costs

ASML Holding NV stock price heads into Monday after January surge — what investors watch next
Next Story

ASML Holding NV stock price heads into Monday after January surge — what investors watch next

Go toTop